Find participating medical centers and current study status in each of them

    Find participating medical centers

    Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

    Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

    • Cancer
    • Tumor
    • Neoplasms
    • Respiratory Tract Neoplasms
    • Gastrointestinal Cancer
    • Lung Cancer
    • Non-Small Cell Lung Cancer (NSCLC)
    • Lung Neoplasm
    • Non Small Cell Lung Carcinoma
    • Neuroendocrine Carcinoma
    • Solid Tumors
    • Carcinoma
    • Adenocarcinoma
    • Thyroid Cancer
    • Medullary Thyroid Cancer
    • Thoracic Neoplasms
    • Head and Neck Cancer
    • Head and Neck Neoplasms

    For the latest version of this information please go to www.forpatients.roche.com